Efficacy and Safety of Ruxolitinib
- Male or female participants aged ≥ 18 years.
- Participants with coronavirus (SARS-CoV-2) infection confirmed ≤ 2 weeks prior to randomization by any test with local regulatory approval.
- Participants who are currently hospitalized, intubated (orotracheal or nasotracheal), and receiving invasive mechanical ventilation due to COVID-19–associated ARDS. Participants must have confirmed PaO2/FiO2 of ≤ 300 mmHg within 6 hours of randomization.
- Participants with lung imaging showing bilateral or diffuse pulmonary infiltrates on chest x-ray or CT scan.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of patients with COVID-19-associated ARDS who require mechanical ventilation. This study is double-blind, which means that during the study you and your study doctor will not know if you are receiving ruxolitinib or placebo.